Q-omics provides the consensus-scored HCRTR2 profile across patient tissues and cancer cell-line models. HCRTR2 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, HCRTR2 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, HCRTR2 protein abundance shows 10,432 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight MESO, KIRC, and UCEC as cancer lineages where HCRTR2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HCRTR2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HCRTR2 survival associations across molecular data types. HCRTR2 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HCRTR2 RNA expression–survival associations across cancer types. High HCRTR2 expression shows unfavorable associations in MESO, DLBC and UCEC, but favorable associations in LGG, LUAD and CESC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for HCRTR2 RNA expression.
This table summarizes HCRTR2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for HCRTR2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HCRTR2 shows lower tumor expression in KIRC, KIRP, KICH, LIHC and LUAD and higher tumor expression in HNSC. The KIRC box plot shows higher HCRTR2 RNA expression in normal versus tumor tissue (log2 FC = −0.735, t-test p < 0.001).
This table shows molecular features associated with HCRTR2 in patient tissues and cancer cell lines. In patient samples, HCRTR2 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, HCRTR2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and CNS.
